Details for Patent: 7,205,302

Which drugs does patent 7,205,302 protect, and when does it expire?

Patent 7,205,302 protects UPTRAVI and is included in two NDAs.

This patent has twenty-one patent family members in sixteen countries.

Summary for Patent: 7,205,302

Title:	Heterocyclic compound derivatives and medicines
Abstract:	The present invention provides a compound which is useful as a PGI.sub.2 receptor agonist, and a pharmaceutical composition. The present invention is directed to a pharmaceutical composition comprising a compound represented by the following formula [1]: ##STR00001## (R.sup.1 and R.sup.2 are the same or different and each represents optionally substituted aryl, Y represents N or CH, Z represents N or CH, A represents NH, NR.sup.5, O, S, or ethylene, R.sup.5 represents alkyl, D represents alkylene or alkenylene, E represents phenylene or single bond, G represents O, S, or CH.sub.2, R.sup.3 and R.sup.4 are the same or different and each represents hydrogen or alkyl, Q represents carboxy, alkoxycarbonyl, tetrazolyl, carbamoyl, or N-(alkylsulfonyl)carbamoyl), or a pharmaceutically acceptable salt thereof as an active ingredient.
Inventor(s):	Asaki; Tetsuo (Kyoto, JP), Hamamoto; Taisuke (Osaka, JP), Kuwano; Keiichi (Osaka, JP)
Assignee:	Nippon Shinyaku Co., Ltd. (Kyoto, JP)
Application Number:	10/476,196
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 7,205,302
Patent Claim Types: see list of patent claims	Composition; Compound; Use;

Drugs Protected by US Patent 7,205,302

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Actelion	UPTRAVI	selexipag	POWDER;INTRAVENOUS	214275-001	Jul 29, 2021		RX	Yes	Yes			Y	Y		METHOD OF TREATING PULMONARY ARTERIAL HYPERTENSION COMPRISING ADMINISTERING A PHARMACEUTICAL COMPOSITION COMPRISING SELEXIPAG
Actelion	UPTRAVI	selexipag	TABLET;ORAL	207947-001	Dec 21, 2015	AB	RX	Yes	No			Y	Y		METHOD OF TREATING PULMONARY ARTERIAL HYPERTENSION COMPRISING ADMINISTERING A PHARMACEUTICAL COMPOSITION COMPRISING SELEXIPAG
Actelion	UPTRAVI	selexipag	TABLET;ORAL	207947-002	Dec 21, 2015	AB	RX	Yes	Yes			Y	Y		METHOD OF TREATING PULMONARY ARTERIAL HYPERTENSION COMPRISING ADMINISTERING A PHARMACEUTICAL COMPOSITION COMPRISING SELEXIPAG
Actelion	UPTRAVI	selexipag	TABLET;ORAL	207947-003	Dec 21, 2015	AB	RX	Yes	No			Y	Y		METHOD OF TREATING PULMONARY ARTERIAL HYPERTENSION COMPRISING ADMINISTERING A PHARMACEUTICAL COMPOSITION COMPRISING SELEXIPAG
Actelion	UPTRAVI	selexipag	TABLET;ORAL	207947-004	Dec 21, 2015	AB	RX	Yes	No			Y	Y		METHOD OF TREATING PULMONARY ARTERIAL HYPERTENSION COMPRISING ADMINISTERING A PHARMACEUTICAL COMPOSITION COMPRISING SELEXIPAG
Actelion	UPTRAVI	selexipag	TABLET;ORAL	207947-005	Dec 21, 2015		RX	Yes	No			Y	Y		METHOD OF TREATING PULMONARY ARTERIAL HYPERTENSION COMPRISING ADMINISTERING A PHARMACEUTICAL COMPOSITION COMPRISING SELEXIPAG
Actelion	UPTRAVI	selexipag	TABLET;ORAL	207947-006	Dec 21, 2015		RX	Yes	No			Y	Y		METHOD OF TREATING PULMONARY ARTERIAL HYPERTENSION COMPRISING ADMINISTERING A PHARMACEUTICAL COMPOSITION COMPRISING SELEXIPAG

Foreign Priority and PCT Information for Patent: 7,205,302

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
Japan	2001-129765	Apr 26, 2001

PCT Information
PCT Filed	April 25, 2002	PCT Application Number:	PCT/JP02/04118
PCT Publication Date:	November 07, 2002	PCT Publication Number:	WO02/088084

International Family Members for US Patent 7,205,302

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Brazil	0209249
Brazil	PI0209249
Canada	2445344
China	1301973
China	1516690
Germany	60217674
Denmark	1400518